Graeme J. Finlay

5.2k citations

101 papers · 4.2k indexed · 1 hit paper · h-index 35

Co-authors: Bruce C. Baguley Marjan Askarian-Amiri William A. Denny Euphemia Leung William R. Wilson Leslie W. Deady Graham J. Atwell Swarna A. Gamage
Topics: Cancer therapeutics and mechanisms (45 papers)Synthesis and Biological Evaluation (19 papers)Bioactive Compounds and Antitumor Agents (13 papers)
Cited by: Toxicology Cell Biology Cancer Research
Journals: PLoS ONE JNCI Journal of the National Cancer Institute Cancer Research
Partner nations: New Zealand Australia United States

In The Last Decade

Graeme J. Finlay

97 papers receiving 4.1k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Signaling Pathways in Melanogenesis

2016 780 citations Graeme J. Finlay, Bruce C. Baguley et al. profile →

Peers

Countries citing papers authored by Graeme J. Finlay

Since Specialization

Citations

This map shows the geographic impact of Graeme J. Finlay's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Graeme J. Finlay with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Graeme J. Finlay more than expected).

Fields of papers citing papers by Graeme J. Finlay

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Graeme J. Finlay. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Graeme J. Finlay. The network helps show where Graeme J. Finlay may publish in the future.

Co-authorship network of co-authors of Graeme J. Finlay

This figure shows the co-authorship network connecting the top 25 collaborators of Graeme J. Finlay. A scholar is included among the top collaborators of Graeme J. Finlay based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Graeme J. Finlay. Graeme J. Finlay is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	Can ECIS Biosensor Technology Be Used to Measure the Cellular Responses of Glioblastoma Stem Cells? 2021 ·Biosensors ·(unknown),Jane Yu,Sungmin Jun,(unknown),Graeme J. Finlay,Catherine E. Angel,E. Scott Graham	9
2	Real-Time Measurement of Melanoma Cell-Mediated Human Brain Endothelial Barrier Disruption Using Electric Cell-Substrate Impedance Sensing Technology 2019 ·Biosensors ·(unknown),(unknown),Rebecca Johnson,Dan T. Kho,Wayne R. Joseph,(unknown),Graeme J. Finlay,Simon J. O’Carroll,Catherine E. Angel,E. Scott Graham	19
3	ZFAS1: a long noncoding RNA associated with ribosomes in breast cancer cells 2016 ·Biology Direct ·(unknown),Euphemia Leung,Bruce C. Baguley,Graeme J. Finlay,David Cameron‐Smith,Vandré C. Figueiredo,Marjan Askarian-Amiri	63
4	Selected GRIN2A mutations in melanoma cause oncogenic effects that can be modulated by extracellular glutamate 2016 ·Cell Calcium ·(unknown),Wayne R. Joseph,Taryn N. Green,Euphemia Leung,Matthew J. During,Graeme J. Finlay,Bruce C. Baguley,Maggie L. Kalev‐Zylinska	11
5	Relationships between Signaling Pathway Usage and Sensitivity to a Pathway Inhibitor: Examination of Trametinib Responses in Cultured Breast Cancer Lines 2014 ·PLoS ONE ·Euphemia Leung,Ji Eun Kim,Marjan Askarian-Amiri,Gordon W. Rewcastle,Graeme J. Finlay,Bruce C. Baguley	24
6	Selective cellular uptake and retention of SN 28049, a new DNA-binding topoisomerase II-directed antitumor agent 2014 ·Cancer Chemotherapy and Pharmacology ·(unknown),(unknown),Wayne R. Joseph,Graeme J. Finlay,James W. Paxton,Mark J. McKeage,Bruce C. Baguley	9
7	Evidence That GRIN2A Mutations in Melanoma Correlate with Decreased Survival 2014 ·Frontiers in Oncology ·(unknown),Jack U. Flanagan,Taryn N. Green,Euphemia Leung,Marjan Askarian-Amiri,Wayne R. Joseph,(unknown),Richard Isaacs,James H. Shaw,(unknown),Matthew J. During,Graeme J. Finlay,Bruce C. Baguley,Maggie L. Kalev‐Zylinska	22
8	Comparison of the effects of the PI3K/mTOR inhibitors NVP-BEZ235 and GSK2126458 on tamoxifen-resistant breast cancer cells 2011 ·Cancer Biology & Therapy ·Euphemia Leung,Ji Eun Kim,Gordon W. Rewcastle,Graeme J. Finlay,Bruce C. Baguley	64
9	Human Evolution: How Random Process Fulfils Divine Purpose 2008 ·Graeme J. Finlay	0
10	Effects of protein binding on the in vitro activity of antitumour acridine derivatives and related anticancer drugs 2000 ·Cancer Chemotherapy and Pharmacology ·Graeme J. Finlay,Bruce C. Baguley	45
11	Cytotoxicity of salicylaldehyde benzoylhydrazone analogs and their transition metal complexes: quantitative structure–activity relationships 1999 ·Journal of Inorganic Biochemistry ·Eric W. Ainscough,Andrew M. Brodie,William A. Denny,Graeme J. Finlay,Scott A. Gothe,John D. Ranford	89
12	Carbamate analogues of amsacrine active against non-cycling cells: relative activity against topoisomerases IIα and β 1999 ·Cancer Chemotherapy and Pharmacology ·(unknown),(unknown),M. Perenna Rogers,Richard B. Lock,Daniel M. Sullivan,Graeme J. Finlay,Bruce C. Baguley,Caroline A. Austin	13
13	Nitrogen, sulfur and oxygen donor adducts with copper(II) complexes of antitumor 2-formylpyridinethiosemicarbazone analogs: Physicochemical and cytotoxic studies 1998 ·Journal of Inorganic Biochemistry ·Eric W. Ainscough,Andrew M. Brodie,William A. Denny,Graeme J. Finlay,John D. Ranford	94
14	Resistance mechanisms determining the in vitro sensitivity to paclitaxel of tumour cells cultured from patients with ovarian cancer 1995 ·European Journal of Cancer ·Bruce C. Baguley,Elaine S. Marshall,J. R. Whittaker,(unknown),(unknown),(unknown),Graeme J. Finlay,J. H. Matthews,Karen M. Holdaway,Pierre van Zijl	46
15	Radiosensitivity of new and established human melanoma cell lines: Comparison of [3H]thymidine incorporation and soft agar clonogenic assays 1994 ·European Journal of Cancer ·Elaine S. Marshall,J. H. Matthews,James H. Shaw,(unknown),(unknown),Graeme J. Finlay,Karen M. Holdaway,Bruce C. Baguley	41
16	Genetics, molecular biology and colorectal cancer 1993 ·Mutation research. Fundamental and molecular mechanisms of mutagenesis ·Graeme J. Finlay	18
17	Unusual dynamics of killing of cultured lewis lung cells by the DNA-intercalating antitumour agentN-[2-(dimethylamino)ethyl]acridine-4-carboxamide 1992 ·Cancer Chemotherapy and Pharmacology ·(unknown),Graeme J. Finlay,J.B. Gavin,Bruce C. Baguley	15
18	Comparison of the cytotoxicity of amsacrine and its analogue CI-921 against cultured human and mouse bone marrow tumour cells 1990 ·European Journal of Cancer and Clinical Oncology ·Lai‐Ming Ching,Graeme J. Finlay,Wayne R. Joseph,Bruce C. Baguley	6
19	Relationship between the structure of analogues of amsacrine and their degree of cross-resistance to adriamycin-resistant P388 leukaemia cells 1988 ·European Journal of Cancer and Clinical Oncology ·Bruce C. Baguley,Graeme J. Finlay	4
20	Derivatives of Amsacrine: Determinants Required for High Activity Against Lewis Lung Carcinoma 1988 ·JNCI Journal of the National Cancer Institute ·Bruce C. Baguley,Graeme J. Finlay	10

About Graeme J. Finlay

Graeme J. Finlay is a scholar working on Toxicology, Oncology and Cancer Research, having authored 101 papers that have together received 4.2k indexed citations. Recurring topics across this work include Cancer therapeutics and mechanisms (45 papers), Synthesis and Biological Evaluation (19 papers) and Bioactive Compounds and Antitumor Agents (13 papers). The work is most often cited by research in Toxicology (315 citations), Cell Biology (769 citations) and Cancer Research (655 citations). Graeme J. Finlay has collaborated with scholars based in New Zealand, Australia and United States. Frequent co-authors include Bruce C. Baguley, Marjan Askarian-Amiri, William A. Denny, Euphemia Leung, William R. Wilson, Leslie W. Deady, Graham J. Atwell, Swarna A. Gamage, Julie A. Spicer and Debina Sarkar. Their work appears in journals such as PLoS ONE, JNCI Journal of the National Cancer Institute and Cancer Research.

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact